Impact of angiotensin blockade on response to PD1/L1 inhibitors for patients with metastatic urothelial carcinoma (mUC).

被引：0
|
作者：
Skelton, William Paul [1 ]
Jain, Rohit K. [2 ]
Curran, Catherine [3 ]
Pond, Gregory Russell [4 ]
Naqvi, Syeda Mahrukh Hussnain [5 ]
Kim, Youngchul [1 ]
Nuzzo, Pier Vitale [3 ]
Abou Alaiwi, Sarah [3 ]
Nassar, Amin [6 ]
Jain, Rakesh K. [7 ]
Sonpavde, Guru [8 ]
机构：
[1] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[2] Lee Moffitt Canc Ctr, Tampa, FL USA
[3] Dana Farber Canc Inst, Boston, MA 02115 USA
[4] McMaster Univ, Dept Oncol, Hamilton, ON, Canada
[5] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[6] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA
[7] Massachusetts Gen Hosp, Boston, MA 02114 USA
[8] Harvard Med Sch, Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 06期
关键词：
D O I：
10.1200/JCO.2021.39.6_suppl.453
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
453
引用
收藏
页数：2
相关论文
共 50 条
  • [21] First-line PD1/PD-L1 inhibitors for platinum-ineligible advanced urothelial carcinoma (UC).
    Agarwal, Archana
    Pond, Gregory Russell
    Drakaki, Alexandra
    Lee, Jae-Lyun
    Bilen, Mehmet Asim
    Di Lorenzo, Giuseppe
    Grivas, Petros
    Ornstein, Moshe Chaim
    Barata, Pedro C.
    Gupta, Shilpa
    Hussain, Syed A.
    Curran, Catherine
    Garcia, Jorge A.
    Sonpavde, Guru
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [22] Significance of PD-L1 in Metastatic Urothelial Carcinoma Treated With Immune Checkpoint Inhibitors
    Maiorano, Brigida Anna
    Di Maio, Massimo
    Cerbone, Linda
    Maiello, Evaristo
    Procopio, Giuseppe
    Roviello, Giandomenico
    JAMA NETWORK OPEN, 2024, 7 (03) : E241215
  • [23] Fibroblast Growth Factor Receptor 3 Alterations and Response to PD-1/PD-L1 Blockade in Patients with Metastatic Urothelial Cancer
    Wang, Li
    Gong, Yixuan
    Saci, Abdel
    Szabo, Peter M.
    Martini, Alberto
    Necchi, Andrea
    Siefker-Radtke, Arlene
    Pal, Sumanta
    Plimack, Elizabeth R.
    Sfakianos, John P.
    Bhardwaj, Nina
    Horowitz, Amir
    Farkas, Adam M.
    Mulholland, David
    Fischer, Bruce S.
    Oh, William K.
    Sharma, Padmanee
    Zhu, Jun
    Galsky, Matthew D.
    EUROPEAN UROLOGY, 2019, 76 (05) : 599 - 603
  • [24] A SYSTEMATIC LITERATURE REVIEW (SLR) TO SUPPORT NETWORK META-ANALYSES (NMA) IN THE TREATMENT OF LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA (LA/MUC) FOLLOWING PD-1/L1 INHIBITORS
    Shah, S. N.
    Wissinger, E.
    Ballew, N.
    Hepp, Z.
    VALUE IN HEALTH, 2019, 22 : S443 - S443
  • [25] The evolving role of PD-L1 testing in patients with metastatic urothelial carcinoma
    Powles, Thomas
    Walker, Jill
    Williams, J. Andrew
    Bellmunt, Joaquim
    CANCER TREATMENT REVIEWS, 2020, 82
  • [26] Pretreatment Eosinophil Counts in Patients With Advanced or Metastatic Urothelial Carcinoma Treated With Anti-PD-1/PD-L1 Checkpoint Inhibitors
    Mota, Jose Mauricio
    Teo, Min Yuen
    Whiting, Karissa
    Li, Han A.
    Regazzi, Ashely M.
    Lee, Chung-Han
    Funt, Samuel A.
    Bajorin, Dean
    Ostrovnaya, Irina
    Iyer, Gopa
    Rosenberg, Jonathan E.
    JOURNAL OF IMMUNOTHERAPY, 2021, 44 (07) : 248 - 253
  • [27] Management of Thyrotoxicosis Induced by PD1 or PD-L1 Blockade
    Brancatella, Alessandro
    Lupi, Isabella
    Montanelli, Lucia
    Ricci, Debora
    Viola, Nicola
    Sgro, Daniele
    Antonangeli, Lucia
    Sardella, Chiara
    Brogioni, Sandra
    Piaggi, Paolo
    Molinaro, Eleonora
    Bianchi, Francesca
    Aragona, Michele
    Antonuzzo, Andrea
    Sbrana, Andrea
    Lucchesi, Maurizio
    Chella, Antonio
    Falcone, Alfredo
    del Prato, Stefano
    Elisei, Rossella
    Marcocci, Claudio
    Caturegli, Patrizio
    Santini, Ferruccio
    Latrofa, Francesco
    JOURNAL OF THE ENDOCRINE SOCIETY, 2021, 5 (09)
  • [28] PD-1 and PD-L1 Inhibitors as Salvage Therapy for Urothelial Carcinoma
    Sonpavde, Guru
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (11): : 1073 - 1074
  • [29] Interrogation of neoantigen-specific CD8 T cells in peripheral blood following PD-L1 blockade in patients with metastatic urothelial carcinoma (mUC).
    Holm, Jeppe Sejero
    Funt, Samuel Aaron
    Bjerregaard, Anne-Mette
    Reading, James L.
    Maher, Colleen Anne
    Regazzi, Ashley Marie
    Wong, Phillip
    Al-Ahmadie, Hikmat
    Overgaard, Nana Haahr
    Tamhane, Tripti
    Bentzen, Amalie Kai
    Snyder, Alexandra
    Merghoub, Taha
    Wolchok, Jedd D.
    Nielsen, Morten
    Rosenberg, Jonathan E.
    Bajorin, Dean F.
    Hadrup, Sine Reker
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [30] Tumor mutational burden related classifier is predictive of response to PD-L1 blockade in locally advanced and metastatic urothelial carcinoma
    Wang, Yejinpeng
    Chen, Liang
    Ju, Lingao
    Xiao, Yu
    Wang, Xinghuan
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2020, 87
12345